Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo

被引:33
作者
Brown, H. K. [1 ]
Ottewell, P. D. [1 ]
Evans, C. A. [1 ]
Holen, I. [1 ]
机构
[1] Univ Sheffield, Acad Unit Clin Oncol, Sch Med, Sheffield S10 2RX, S Yorkshire, England
关键词
Breast cancer; Bone metastasis; Osteoblast; Osteoclast; Osteolysis; Bone microenvironment; NITROGEN-CONTAINING BISPHOSPHONATES; ZOLEDRONIC ACID; BONE METASTASIS; MOUSE MODEL; TUMOR; ACTIVATION; EXPRESSION; OSTEOLYSIS; DISEASE; MYELOMA;
D O I
10.1007/s10585-012-9481-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone metastasis is a common incurable complication of breast cancer affecting around 70% of patients with advanced disease. In order to improve outcomes for these patients, the cellular and molecular mechanisms underlying bone metastasis need to be established. The majority of studies to date have focused on end-stage disease and little is known about the events taking place following initial tumour cell colonisation of bone. Here we report the results of a longitudinal study that provides detailed analysis of the spatial and temporal relationship between bone and cancer cells during progression of bone metastasis. Tumour growth in bone was initiated by intra-cardiac inoculation of MDA-MB-231-GFP breast cancer cells in immunocompromised mice. Differentiating between areas of bone in direct contact with the tumour and areas distal to the cancer cells but within the tumour bearing bone, we performed comprehensive analyses of the number and distribution of osteoclasts and osteoblasts. Tumour colonies were detectable in bone from day 10, while reduced trabecular bone volume was apparent from day 19 onwards. Cancer-induced changes in osteoblast and osteoclast numbers differed substantially depending on whether or not the cells were in direct contact with the tumour. Compared to na < ve controls, areas of bone in direct contact with the tumour had significantly reduced osteoblast but increased osteoclast numbers, whereas the reverse was found in distal areas. Our data demonstrate that tumour cells induce substantial changes in the bone microenvironment prior to the appearance of bone lesions, suggesting that early therapeutic intervention may be required to oppose the tumour-induced changes to the microenvironment und thus tumour progression.
引用
收藏
页码:927 / 938
页数:12
相关论文
共 34 条
[1]   RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor, metastasis genes [J].
Armstrong, Allison P. ;
Miller, Robert E. ;
Jones, Jon C. ;
Zhang, Jian ;
Keller, Evan T. ;
Dougall, William C. .
PROSTATE, 2008, 68 (01) :92-104
[2]  
Bodenstine Thomas M, 2011, Chin J Cancer, V30, P189
[3]   Inhibiting Activin-A Signaling Stimulates Bone Formation and Prevents Cancer-Induced Bone Destruction In Vivo [J].
Chantry, Andrew D. ;
Heath, Debby ;
Mulivor, Aaron W. ;
Pearsall, Scott ;
Baud'huin, Marc ;
Coulton, Les ;
Evans, Holly ;
Abdul, Nicole ;
Werner, Eric D. ;
Bouxsein, Mary L. ;
Key, Michelle L. ;
Seehra, Jasbir ;
Arnett, Timothy R. ;
Vanderkerken, Karin ;
Croucher, Peter .
JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (12) :2357-2370
[4]  
Clohisy DR, 1996, J ORTHOPAED RES, V14, P396
[5]   Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts [J].
Clohisy, DR ;
Ogilvie, CM ;
Carpenter, RJ ;
Ramnaraine, MLR .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1996, 14 (01) :2-6
[6]   Breast-Cancer Adjuvant Therapy with Zoledronic Acid [J].
Coleman, Robert E. ;
Marshall, Helen ;
Cameron, David ;
Dodwell, David ;
Burkinshaw, Roger ;
Keane, Maccon ;
Gil, Miguel ;
Houston, Stephen J. ;
Grieve, Robert J. ;
Barrett-Lee, Peter J. ;
Ritchie, Diana ;
Pugh, Julia ;
Gaunt, Claire ;
Rea, Una ;
Peterson, Jennifer ;
Davies, Claire ;
Hiley, Victoria ;
Gregory, Walter ;
Bell, Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15) :1396-1405
[7]  
Corey E, 2003, CLIN CANCER RES, V9, P295
[8]   Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298 [J].
Coxon, FP ;
Helfrich, MH ;
Van't Hof, R ;
Sebti, S ;
Ralston, SH ;
Hamilton, A ;
Rogers, MJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1467-1476
[9]   Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival [J].
Croucher, PI ;
De Raeve, H ;
Perry, MJ ;
Hijzen, A ;
Shipman, CM ;
Lippitt, J ;
Green, J ;
Van Marck, E ;
Van Camp, B ;
Vanderkerken, K .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (03) :482-492
[10]   Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis [J].
Daubine, Florence ;
Le Gall, Celine ;
Gasser, Juerg ;
Green, Jonathan ;
Clezardin, Philippe .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (04) :322-330